Elekta Axesse SBRT linear accelerator.

April 6, 2010 - The three-year survival rate for patients receiving stereotactic body radiation therapy (SBRT) was 55.8 percent, compared to the 20-35 percent two-year to three-year overall survival rate for studies reporting results from conventional radiation therapy for similar patient groups, a recent study found.

Lead investigator, Robert Timmerman, M.D., conducted a study using SBRT to treat nearly 60 patients with inoperable early stage lung cancer. The study 2004-2006 Radiation Therapy Oncology Group (RTOG 0236) study was a Phase 2 North American trial of patients with nonsmall cell lung tumors where pre-existing medical conditions precluded surgical treatment.

According to Dr. Timmerman, the main finding in this study was the high rate of primary tumor control, which is 97.6 percent at three years. "SBRT as delivered in this trial provided more than double the rate of primary tumor control than previous reports describing conventional radiation therapy. Primary tumor control is essential for curing lung cancer," he said.

Dr. Timmerman and his team used Elekta SBRT solutions. The system is designed to integrate advanced technologies to enable a radiation therapy treatment technique that delivers highly sculpted dose distributions with exceptional precision.

For more information: www.elekta.com

Related Content

News | Quality Assurance (QA)

October 11, 2021 — To maintain safety in radiation therapy (RT), every machine performance and patient delivery ...

Time October 11, 2021
arrow
News | Radiation Therapy

October 7, 2021 — NANOBIOTIX, a late-stage clinical biotechnology company pioneering physics-based approaches to expand ...

Time October 07, 2021
arrow
Feature | Radiation Therapy | By Dave Fornell

To maintain safety in radiation therapy (RT), every machine performance and patient delivery measurement must be as ...

Time October 05, 2021
arrow
Feature | Radiation Therapy

September 28, 2021 — New research from Washington University School of Medicine in St. Louis suggests that radiation ...

Time September 28, 2021
arrow
News | Radiation Oncology

September 28, 2021 — The global radiotherapy devices market is expected to grow from $5.44 billion in 2020 to $5.848 ...

Time September 28, 2021
arrow
News | Prostate Cancer

September 24, 2021 — Scientists have identified two subtypes of metastatic prostate cancer that respond differently to ...

Time September 24, 2021
arrow
News | Radiation Therapy

September 24, 2021 — The "Global Surface Guided Radiation Therapy (SGRT) Devices Market, By Device Type (Portable v/s ...

Time September 24, 2021
arrow
News | Lung Imaging

September 23, 2021 — The National Cancer Institute announced that Virginia Commonwealth University Massey Cancer Center ...

Time September 23, 2021
arrow
News | Radiation Oncology

September 21, 2021 — The development of new research guidelines for interventional oncology that standardize treatment ...

Time September 21, 2021
arrow
News | Radiation Oncology

September 20, 2021 — The rapid pace of developments in the oncology field, mainly brought by cancer immunotherapy, means ...

Time September 20, 2021
arrow
Subscribe Now